Neuron23 emerges from stealth with $113.5M
December 17, 2020- Share:
Neuron23 has announced $33.5 million in Series A funding from WestLake Village BioPartners and Kleiner Perkins, and $80 million in a round led by Redmile Group, with participation from investors including Westlake, Kleiner Perkins, Cowen Healthcare Investments and Acorn Bioventures. Founded in 2018, the San Francisco-based biotech startup is developing precision medicines for neurological and immunological diseases; it plans to use the funding in part to develop new biomarkers for the treatment of neurodegenerative diseases.
Additional Investors
- Share:
-
-
-
-